FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma

• DOI: 10.3389/fonc.2021.756843
• Publication Date: 2021-12-09T05:18:15Z
• Authors: Zheng Lv; Bo Cui; Xing Huang; Hua-Yi Feng; Tao Wang; Han-Feng Wang; Yun-Dong Xuan; Hong-Zhao Li; Xin Ma; Yan Huang; Xu Zhang
• Keywords: Tumor progression

Clear cell renal carcinoma (ccRCC), which is the most prevalent subtype, has a poor prognosis. Emerging strategies for enhancing immune response in ccRCC therapy are currently being investigated. Fibrinogen-like Protein 1(FGL1) novel mechanism that tumors may use to evade system by binding LAG-3 and negatively regulating T cells. In this study, we aimed at investigating underlying of FGL1 ccRCC, its expression prognostic value. We found was upregulated tumor tissues plasma specimens patients. High predicted prognosis also discovered overexpression enhances RCC migration, invasion, metastasis activating epithelial-to-mesenchymal transition (EMT). Consistent with these results, identified significant positive correlation between EMT-related genes through tissue microarray analysis. Gene-expression analysis revealed FGL1-deficient lines had altered transcriptional output inflammatory response, cell-cell signaling, negative regulation activation, intracellular signal transduction. Depletion significantly inhibited growth lung orthotopic xenograft mouse model. Infiltration myeloid-derived CD11b+ Ly6G+ cells microenvironment (TME) strikingly decreased when reduced. Therefore, increased positively correlated Mechanistically, facilitates EMT process modulates TME, promotes progression metastasis. Consequently, targeting can potentially improve clinical outcome